Bristol-Myers Squibb Co Stock Forecast for 2023 - 2025 - 2030
Updated on 06/04/2023
Bristol-Myers Squibb Co Stock Forecast and Price Target
If the average 2023 price target of $83.00 recently set by thridteen prominent experts for Bristol-Myers Squibb Co is met, there would be a potential upside of approximately 26.41% from the last closing price in June, 2023. The high estimate is $95.00, and the low is $60.00. If you're looking for information on Bristol-Myers Squibb Co stock, consider checking out the forecasts for comparable firms such as NasdaqGS:REGN.
26.41% Upside
Bristol-Myers Squibb Co Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Bristol-Myers Squibb Co's Price has grown, rising from $47.79 to $76.53 – a growth of 60.13%. In the next year, analysts believe that Fair Value will reach $83.86 – an increase of 9.59%. By 2030, professionals predict that Bristol-Myers Squibb Co's Fair Value will decrease by 8.79%, to $69.80.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$156.97 | Buy/Sell | $178.79 | 14.99% |
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$442.33 | Buy/Sell | $333.19 | -9.57% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$38.36 | Buy/Sell | $47.96 | 37.25% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$112.52 | Buy/Sell | $99.57 | 4.87% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$739.95 | Buy/Sell | $796.73 | 5.68% |
Bristol-Myers Squibb Co Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb Co's Revenue has grown, rising from $26.15B to $46.16B – a growth of 76.55%. In the next year, analysts believe that Revenue will reach $48.66B – an increase of 5.42%. By 2030, professionals predict that Bristol-Myers Squibb Co's Revenue will decrease by 20.06%, to $36.90B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$333.78 | Buy/Sell | $363.29 | -2.33% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$171.88 | Buy/Sell | $209.70 | 19.27% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.33 | Buy/Sell | $60.73 | 40.33% |
.jpg)
Bristol-Myers Squibb Co Dividend per Share Forecast for 2023 - 2025 - 2030
Bristol-Myers Squibb Co's Dividend per Share has grown In the last three years, rising from $1.68 to $2.28 – a growth of 35.71%. For the following year, the 10 analysts predict that Bristol-Myers Squibb Co's Dividend per Share will drop by 1.32%, reaching $2.25. In 2030, the professionals' prediction is that BMY's Dividend per Share will decrease by 7.89%, reaching $2.10.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$193.67 | Buy/Sell | $244.18 | 29.60% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$9.33 | Buy/Sell | $13.70 | 44.69% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$217.22 | Buy/Sell | $280.69 | 35.81% |
Bristol-Myers Squibb Co Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb Co's Free Cash Flow has grown by 197613122.50%, rising from $7.37B to $14572.00T. The next year, 7 experts forecast that Bristol-Myers Squibb Co's Free Cash Flow will decrease by 100.00%, reaching $19.68B. In 2030, professionals predict that Bristol-Myers Squibb Co's Free Cash Flow will decrease by 100.00%, reaching $14.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$37.72 | Buy/Sell | $83.92 | 93.53% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.75 | Buy/Sell | $52.42 | 19.76% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$38.63 | Buy/Sell | $62.67 | 55.32% |
Bristol-Myers Squibb Co Net Income Forecast for 2023 - 2025 - 2030
Bristol-Myers Squibb Co's Net Income has seen impressive growth In the last three years, rising from $3.44B to $6.35B – a growth of 84.50%. In the next year, analysts believe that Net Income will reach $17.26B – an increase of 172.08%. For the next eight years, the forecast is for Net Income to grow by 109.51%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$132.82 | Buy/Sell | $163.67 | 23.48% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$18.51 | Buy/Sell | $37.00 | 37.76% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$23.26 | Buy/Sell | $0.00 | 26.83% |
Bristol-Myers Squibb Co EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb Co's EBITDA has grown, moving from $6.30B to $19.92B – an increase of 216.34%. In the next year, analysts predict that EBITDA will jump to $21.50B – up 7.91% from the current level. By 2030, professionals believe that Bristol-Myers Squibb Co's EBITDA will have decreased by 30.31%, falling to $13.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$26.56 | Buy/Sell | $73.38 | -28.46% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£165.80 | Buy/Sell | £3.79 | -97.14% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$39.09 | Buy/Sell | $79.67 | 99.54% |
Bristol-Myers Squibb Co EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Bristol-Myers Squibb Co's EBIT has seen an increase, rising from $4.58B to $9.82B. This represents a growth of 114.59%. Analysts predict that Bristol-Myers Squibb Co's EBIT will increase in the upcoming year, reaching $20.34B. This would represent an increase of 107.11%. Over the next eight years, experts predict that Bristol-Myers Squibb Co's EBIT will grow at a rate of 54.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$46.70 | Buy/Sell | $41.00 | -5.78% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$11.03 | Buy/Sell | $12.60 | 13.33% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$33.53 | Buy/Sell | $35.50 | 1.40% |
Bristol-Myers Squibb Co EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Bristol-Myers Squibb Co's EPS has grown, rising from $4.69 to $7.51 – a growth of 60.13%. In the next year, analysts believe that EPS will reach $8.23 – an increase of 9.59%. By 2030, professionals predict that Bristol-Myers Squibb Co's EPS will decrease by 8.79%, to $6.85.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$72.13 | Buy/Sell | $195.43 | 119.74% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$259.94 | Buy/Sell | $170.08 | -32.68% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$63.54 | Buy/Sell | $104.00 | -10.29% |
Site Navigation
.jpg)